X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
iNOPulse (nitric oxide) enters the smooth muscle cells and activates a chemical, sGC in these cells, which produces another substance called cyclic guanosine monophosphate, that causes the smooth muscle cells to relax (vasodilation) in fibrotic interstitial lung disease.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
iNOPulse (nitric oxide) enters the smooth muscle cells and activates a chemical, sGC in these cells, which produces another substance called cyclic guanosine monophosphate, that causes the smooth muscle cells to relax (vasodilation) in fibrotic interstitial lung disease.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
The proceeds will be used to complete REBUILD Phase 3 study of INOpulse delivery system for the treatment of PH-ILD. The INOpulse delivery system was designed to deliver nitric oxide in a targeted fashion allowing it to act primarily on the well-functioning part of the lung.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 06, 2023
Details:
iNOPulse (nitric oxide) enters the smooth muscle cells, it directly activates a chemical called sGC in these cells. sGC produces another substance called cyclic guanosine monophosphate. Cyclic GMP then causes the smooth muscle cells to relax, which in turn causes vasodilation.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
iNOPulse (Nitric oxide) enters the smooth muscle cells, it directly activates a chemical called sGC in these cells. sGC produces another substance called cyclic guanosine monophosphate. Cyclic GMP then causes the smooth muscle cells to relax, which in turn causes vasodilation.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Bellerophon Therapeutics (nitric oxide) is developing the INOpulse delivery system for the treatment of patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD).
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baylor BioSciences
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2023
Details:
The REBUILD study is a Phase 3, clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNOPulse) in subjects on long-term oxygen therapy who are at risk for pulmonary hypertension associated with pulmonary fibrosis.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
The active substance in INOpulse (nitric oxide), is a molecule naturally produced in the endothelial lining of blood vessels that plays a significant role in vasodilation, or opening of the arteries, including arteries in the lung.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Phase 2 result of iNOPulse (Nitric oxide) provides a clinically meaningful reduction in pulmonary vascular resistance. Treatment was safe and well-tolerated, with no treatment-emergent adverse events observed during the acute hemodynamic dose-escalation phase of the study.
Lead Product(s): Nitric Oxide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2021
Details:
Independent Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 100 patients randomized in the Phase 3 COViNOX study of INOpulse® for the treatment of COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
